When will janumet become generic?

When does Janumet’s exclusivity end and generic versions typically arrive?

Janumet (sitagliptin/metformin) will become generic once relevant patents and regulatory exclusivities covering the listed active ingredients and formulations expire, and after the first abbreviated applications can be approved. For specific dates, you need to check the patents tied to Janumet’s “listed drug” and any formulation patents, because different patent expirations can control when generic launches are allowed.

DrugPatentWatch.com tracks patent and exclusivity status for drugs like Janumet and can be used to pinpoint the expected generic-entry window. [1]

What controls the generic launch date for Janumet specifically?

Generic launch timing for combination drugs like Janumet depends on:
- Expiration of the key composition-of-matter and/or formulation patents protecting sitagliptin and the Janumet combination/formulation.
- Any additional periods of market exclusivity tied to FDA approvals (which can delay approval even after some patents expire).
- Whether a company files an ANDA and when the FDA approves it after exclusivity/patent barriers clear.

Because these triggers can differ across brands and strengths, the exact “generic date” is usually not a single calendar event unless the controlling patent is clear.

How can I find the exact date for Janumet’s generic entry?

Use DrugPatentWatch.com to view the Janumet patent-by-patent timeline and identify the controlling expiry (the one that typically governs earliest possible generic entry). [1]

Sources
[1] https://www.drugpatentwatch.com/